M2696

Metyrapone

≥98% (HPLC), glucocorticoid synthesis inhibitor, solid

• Sinonimo/i: Su-4885
• Formula empirica (notazione di Hill): C₁₄H₁₄N₂O
• Numero CAS: 54-36-4
• Peso molecolare: 226.27
• NACRES: NA.77
• PubChem Substance ID: 329817949
• UNSPSC Code: 51111800
• EC Number: 200-206-2
• MDL number: MFCD00006397
• Beilstein/REAXYS Number: 163023
• Assay: ≥98% (HPLC)
• Form: solid

Proprietà

• Nome del prodotto: Metyrapone, ≥98% (HPLC), solid
• sterility: non-sterile
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• technique(s): toxicology assay: suitable
• mp: 52-55 °C (lit.)
• solubility: H₂O: <2 mg/mL, DMSO: >20 mg/mL
• originator: Novartis
• shipped in: ambient
• storage temp.: room temp
• SMILES string: CC(C)(c1cccnc1)C(=O)c2cccnc2
• InChI: 1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3
• InChI key: FJLBFSROUSIWMA-UHFFFAOYSA-N

Descrizione

Biochem/physiol Actions

Metyrapone is a glucocorticoid synthesis inhibitor; a standard in assessing adrenal gland function especially in response to stress, as well as pituitary gland function. In addition to acting as a glucocorticoid synthesis inhibitor, Metyrapone also inhibits cytochrome P450-mediated prostaglandin ω/ω-1 hydroxylase activity and impairs learning and memory. Data shows results in activation of the sleep EEG and a robust decrease in quantitative delta sleep.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informazioni sulla sicurezza

• pictograms: GHS07
• signalword: Warning
• hcodes: H302,H315,H319,H335
• pcodes: P261 - P264 - P271 - P301 + P312 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Classe di stoccaggio: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves